• Home
• About Lipoxen
• Our Technologies
• Pipeline
• Partnering
• Corporate Governance
• Investor Centre
• News
  • FAQ
  • Contact us
  • Careers

Additional listing and Total Voting Right

01 October 2009

London, UK, 1 October 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and siRNA delivery, announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 100,000 ordinary shares of 0.5p each (the "New Ordinary Shares").

The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.

It is expected that dealings in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 2 October 2009.

In conformity with the FSA's Disclosure and Transparency Rules, the Company notifies the market of the following:

Following the admission to trading on AIM of the Ordinary Shares mentioned above Lipoxen's capital consists of 154,210,085 ordinary shares of 0.5p each ("Ordinary Shares") with voting rights. No Ordinary Shares are held in treasury, therefore the total number of voting rights in the Company is 154,210,085.

The above figure (154,210,085) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Lipoxen under the FSA's Disclosure and Transparency Rules.

Enquiries: